Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

GL Biochem Reaches Final Terms for Reverse Merger

publication date: Jan 5, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
GL Biochem, a Shanghai peptide company, has signed a definitive agreement to complete a reverse merger with Commonwealth Biotechnologies, Inc. GL Biochem is the world’s largest supplier of research-grade peptide products and peptide reagents. Its single shareholder will own 78% of the new company’s stock, post-merger. Dr. Hongyan Xu, Founder, Chairman, and CEO of the GL Group, will become Chairman and CEO of CBI, and GL Biochem will control five of seven seats on the Board of Directors. More details...

Stock Symbol: (NSDQ: CBTE)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
ChinaBio Leadership Retreat 2014
Suzhou, China
October 23-24, 2014
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors